Repare Therapeutics INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
BVF Partners and affiliated entities have disposed of all their common shares in Repare Therapeutics Inc. following its acquisition by XenoTherapeutics, Inc. for cash and contingent value rights.
A director of Repare Therapeutics Inc. reported the disposition of common shares and stock options as part of an Arrangement Agreement for the company's acquisition.
Repare Therapeutics director Ann D. Rhoads reported the disposition of 4,000 common shares as part of an acquisition by XenoTherapeutics, Inc. for $2.20 cash and one CVR per share.
Repare Therapeutics Director Thomas Civik sold 7,500 shares as part of the company's acquisition by Xeno Acquisition Corp. for $2.20 cash and a CVR.
Repare Therapeutics' EVP and CFO, Steve Forte, disposed of all his common shares and cancelled all stock options as part of the company's acquisition by Xeno Acquisition Corp. for $2.20 cash and one CVR per share.
Repare Therapeutics SVP of Finance and CAO, Sandra Isabelle Barros Alves, reported the disposition of common shares and options following the company's acquisition by Xeno Acquisition Corp.
Sandra Isabelle Barros Alves, SVP, Finance and CAO of Repare Therapeutics Inc., reports the acquisition of stock options and restricted stock units.
Steve Forte, EVP and CFO of Repare Therapeutics, was granted 500,000 employee stock options on April 2, 2025, vesting fully on April 2, 2026.
Maria Koehler, EVP, CHIEF MEDICAL OFFICER of Repare Therapeutics Inc., reports selling 3,596 common shares to cover tax obligations related to vesting restricted stock units.
Michael Zinda, EVP and Chief Scientific Officer of Repare Therapeutics, sold 5,611 common shares to cover tax obligations related to vesting restricted stock units.
Steve Forte, EVP and CFO of Repare Therapeutics Inc., sold 6,884 common shares on March 12, 2025, to cover tax obligations related to vesting restricted stock units.
Repare Therapeutics CEO, Lloyd Mitchell Segal, sold shares to cover tax obligations related to the vesting of restricted stock units.
Lloyd Mitchell Segal, President and CEO of Repare Therapeutics Inc., reports the acquisition of stock options and restricted stock units, along with transactions in common shares.
Michael Zinda, EVP and Chief Scientific Officer of Repare Therapeutics Inc., reports acquisition of shares and stock options.
Steve Forte, EVP and CFO of Repare Therapeutics, reports the acquisition of stock options and a restricted stock unit award, along with adjustments to his holdings of common shares.
Director Carol Schafer of Repare Therapeutics Inc. acquired stock options exercisable for 27,200 common shares on June 17, 2024.
Director Ann D. Rhoads of Repare Therapeutics Inc. reports the acquisition of stock options.
Director Briggs Morrison acquired 27,200 stock options in Repare Therapeutics Inc. on June 17, 2024.
Director Susan Molineaux acquired stock options for 27,200 common shares of Repare Therapeutics Inc. on June 17, 2024.
Director Samarth Kulkarni of Repare Therapeutics Inc. [RPTX] acquired stock options on June 17, 2024.
Director Bonita David P of Repare Therapeutics Inc. was granted stock options to purchase 27,200 common shares on June 17, 2024.
Director Thomas Civik acquired stock options in Repare Therapeutics Inc. on June 17, 2024.
Director Steven H. Stein acquired stock options for 54,000 common shares of Repare Therapeutics Inc. on June 17, 2024.
Repare Therapeutics' CEO, Lloyd Mitchell Segal, sold shares on March 28, 2024, and April 1, 2024, to cover tax obligations related to vested restricted stock units.
Steve Forte, EVP and CFO of Repare Therapeutics, sold shares on March 28, 2024, and April 1, 2024, to cover tax obligations related to vested restricted stock units.
Michael Zinda, EVP, CHIEF SCIENTIFIC OFFICER of Repare Therapeutics Inc., sold shares to cover tax obligations related to vested restricted stock units.
Form 4: Repare Therapeutics EVP, Chief Medical Officer Maria Koehler Sells Shares to Cover Tax Obligations
Maria Koehler, EVP and Chief Medical Officer of Repare Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.
Steve Forte, EVP and CFO of Repare Therapeutics, sold a portion of his common shares to cover tax obligations related to the vesting of restricted stock units.
Michael Zinda, EVP and Chief Scientific Officer of Repare Therapeutics, sold common shares between March 25 and March 27, 2024, to cover tax obligations related to vested restricted stock units.
Maria Koehler, EVP, CHIEF MEDICAL OFFICER of Repare Therapeutics Inc., reports selling common shares to cover tax obligations related to vested restricted stock units.